4d Molecular Therapeutics, Inc.
Ticker: FDMT
| Insider | Title |
|---|---|
| August J Moretti | Chief Financial Officer |
| Carolyne Zimmermann | Chief Business Officer |
| Charles Theuer | Director |
| David C. Ott | 10% or greater ownership |
| David Kirn | Chief Executive Officer, Director |
| David Schaffer | Director |
| Fariborz Kamal | President and COO |
| Global Investors Lp Viking | 10% or greater ownership |
| Global Opportunities Gp Llc Viking | 10% or greater ownership |
| Global Opportunities Illiquid Investments Sub-master Lp Viking | 10% or greater ownership |
| Global Opportunities Parent Gp Llc Viking | 10% or greater ownership |
| Global Opportunities Portfolio Gp Llc Viking | 10% or greater ownership |
| Gp Holdings Llc Bvf | See Explanation of Responses |
| I Gp Llc Bvf | See Explanation of Responses |
| Ii Gp Llc Bvf | See Explanation of Responses |
| Inc/il Bvf | See Explanation of Responses |
| Jacob Chacko | Director |
| John F Milligan | Director |
| Mark N Lampert | See Explanation of Responses |
| Nancy Miller-rich | Director |
| Noriyuki Kasahara | Director |
| Ole Andreas Halvorsen | 10% or greater ownership |
| Partners L P/il Bvf | See Explanation of Responses |
| Partners Os Ltd. Bvf | See Explanation of Responses |
| Robert S Fishman | Chief Medical Officer |
| Robert Young Kim | Chief Medical Officer |
| Rose Sharon Shabet | 10% or greater ownership |
| Scott Bizily | Chief Legal Officer |
| Shawn Tomasello | Director |
| Susannah Gray | Director |
| Uneek Mehra | See Remarks |
| Value Fund Ii Lp Biotechnology | See Explanation of Responses |
| Value Fund L P Biotechnology | See Explanation of Responses |
| Value Trading Fund Os Lp Biotechnology | See Explanation of Responses |